EXPEDITED REVIEW
Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents
An Observational Study of Drug-Eluting Versus Bare-Metal Stents
Matthias Pfisterer, MD, FACC*,*,
Hans Peter Brunner-La Rocca, MD*,
Peter T. Buser, MD, FACC*,
Peter Rickenbacher, MD ,
Patrick Hunziker, MD ,
Christian Mueller, MD ,
Raban Jeger, MD*,
Franziska Bader, RN*,
Stefan Osswald, MD, FACC*,
Christoph Kaiser, MD* for the BASKET-LATE Investigators
* Departments of Cardiology
Intensive Care Medicine
Internal Medicine, University Hospital
Bruderholzspital, Basel, Switzerland
Manuscript received June 6, 2006;
revised manuscript received August 24, 2006,
accepted August 28, 2006.
* Reprint requests and correspondence: Dr. Matthias Pfisterer, Professor of Cardiology, Head Department of Cardiology, University Hospital, CH-4031 Basel, Switzerland (Email: pfisterer{at}email.ch).
OBJECTIVES: We sought to define the incidence of late clinical events and late stent thrombosis in patients treated with drug-eluting (DES) versus bare-metal stents (BMS) after the discontinuation of clopidogrel as well as their timing and outcome.
BACKGROUND: There is growing concern that delayed endothelialization after DES implantation may lead to late stent thrombosis and related myocardial infarction (MI) or death. However, event rates and outcomes after clopidogrel discontinuation versus BMS are unknown.
METHODS: A consecutive series of 746 nonselected patients with 1,133 stented lesions surviving 6 months without major events were followed for 1 year after the discontinuation of clopidogrel. Patients were assigned randomly 2:1 to DES versus BMS in BASKET (Basel Stent Kosten Effektivitäts Trial). The primary focus of this observation was cardiac death/MI.
RESULTS: Rates of 18-month cardiac death/MI were not different between DES and BMS patients. However, after the discontinuation of clopidogrel (between months 7 and 18), these events occurred in 4.9% after DES versus 1.3% after BMS implantation. Target vessel revascularization remained lower after DES, resulting in similar rates of all clinical events for this time period (DES 9.3%, BMS 7.9%). Documented late stent thrombosis and related death/target vessel MI were twice as frequent after DES versus BMS (2.6% vs. 1.3%). Thrombosis-related events occurred between 15 and 362 days after the discontinuation of clopidogrel, presenting as MI or death in 88%.
CONCLUSIONS: After the discontinuation of clopidogrel, the benefit of DES in reducing target vessel revascularization is maintained but has to be balanced against an increase in late cardiac death or nonfatal MI, possibly related to late stent thrombosis.
|
Abbreviations and Acronyms
| | BASKET = Basel Stent Kosten Effektivitäts Trial | | BASKET-LATE = BASKET LAte Thrombotic Events Trial | | BMS = bare-metal stent | | CI = confidence interval | | DES = drug-eluting stent | | HR = hazard ratio | | MI = myocardial infarction | | OR = odds ratio | | TVR = target vessel revascularization |
|
Related Article
-
Late Ischemic Events After Clopidogrel Cessation Following Drug-Eluting Stenting: Should We Be Worried?
- Robert A. Harrington and Robert M. Califf
J. Am. Coll. Cardiol. 2006 48: 2592-2595.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
P. O. Vandvik, A. M. Lincoff, J. M. Gore, D. D. Gutterman, F. A. Sonnenberg, P. Alonso-Coello, E. A. Akl, M. G. Lansberg, G. H. Guyatt, and F. A. Spencer
Primary and Secondary Prevention of Cardiovascular Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Chest,
February 1, 2012;
141(2_suppl):
e637S - e668S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-C. Gwon, J.-Y. Hahn, K. W. Park, Y. B. Song, I.-H. Chae, D.-S. Lim, K.-R. Han, J.-H. Choi, S.-H. Choi, H.-J. Kang, et al.
Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study
Circulation,
January 24, 2012;
125(3):
505 - 513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Angiolillo, M. S. Firstenberg, M. J. Price, P. E. Tummala, M. Hutyra, I. J. Welsby, M. D. Voeltz, H. Chandna, C. Ramaiah, M. Brtko, et al.
Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery: A Randomized Controlled Trial
JAMA,
January 18, 2012;
307(3):
265 - 274.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. A. Ali, A. Kini, and S. K. Sharma
On OCT and Finding the Uncovered Tracks...
J. Am. Coll. Cardiol. Img.,
January 1, 2012;
5(1):
83 - 86.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. Granada, M. J. Price, P. A. French, S. R. Steinhubl, D. E. Cutlip, R. C. Becker, S. S. Smyth, and H. L. Dauerman
Platelet-Mediated Thrombosis and Drug-Eluting Stents
Circ Cardiovasc Interv,
December 1, 2011;
4(6):
629 - 637.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. de Prado, C. Perez-Martinez, C. Cuellas-Ramon, J. M. Gonzalo-Orden, M. Regueiro-Purrinos, B. Martinez, M. J. Garcia-Iglesias, J. M. Ajenjo, J. R. Altonaga, A. Diego-Nieto, et al.
Time Course of Reendothelialization of Stents in a Normal Coronary Swine Model: Characterization and Quantification
Veterinary Pathology,
November 1, 2011;
48(6):
1109 - 1117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Gutierrez-Chico, R. J. van Geuns, E. Regar, W. J. van der Giessen, H. Kelbaek, K. Saunamaki, J. Escaned, N. Gonzalo, C. di Mario, F. Borgia, et al.
Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial
Eur. Heart J.,
October 1, 2011;
32(19):
2454 - 2463.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Gaglia Jr and R. Waksman
Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes
Eur. Heart J.,
October 1, 2011;
32(19):
2358 - 2364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Kandzari, C. S. Barker, M. B. Leon, L. Mauri, W. Wijns, J. Fajadet, and R. Mehran
Dual Antiplatelet Therapy Duration and Clinical Outcomes Following Treatment With Zotarolimus-Eluting Stents
J. Am. Coll. Cardiol. Intv.,
October 1, 2011;
4(10):
1119 - 1128.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Gutierrez-Chico, E. Regar, E. Nuesch, T. Okamura, J. Wykrzykowska, C. di Mario, S. Windecker, G.-A. van Es, P. Gobbens, P. Juni, et al.
Delayed Coverage in Malapposed and Side-Branch Struts With Respect to Well-Apposed Struts in Drug-Eluting Stents: In Vivo Assessment With Optical Coherence Tomography
Circulation,
August 2, 2011;
124(5):
612 - 623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Raghuram, C. Seynnaeve, and A. T. Rai
Endovascular treatment of extracranial atherosclerotic disease involving the vertebral artery origins: a comparison of drug-eluting and bare-metal stents
JNIS,
June 28, 2011;
(2011)
neurintsurg-2011-010051v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Guo, Z. Lu, Y. Zhang, S. Li, and J. Yang
In vivo study on the histocompatibility and degradation behavior of biodegradable poly(trimethylene carbonate-co-D,L-lactide)
Acta Biochim Biophys Sin,
June 1, 2011;
43(6):
433 - 440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Wright, J. L. Anderson, C. D. Adams, C. R. Bridges, D. E. Casey Jr, S. M. Ettinger, F. M. Fesmire, T. G. Ganiats, H. Jneid, A. M. Lincoff, et al.
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
J. Am. Coll. Cardiol.,
May 10, 2011;
57(19):
e215 - e367.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al.
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Circulation,
May 10, 2011;
123(18):
e426 - e579.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Ahmed, H. L. Dauerman, W. D. Piper, J. F. Robb, M. P. Verlee, T. J. Ryan Jr, D. Goldberg, R. A. Boss Jr, W. J. Phillips, F. Fedele, et al.
Recent Changes in Practice of Elective Percutaneous Coronary Intervention for Stable Angina
Circ Cardiovasc Qual Outcomes,
May 1, 2011;
4(3):
300 - 305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ikesue, Y. Matsui, D. Ohta, K. Danzaki, K. Ito, M. Kanayama, D. Kurotaki, J. Morimoto, T. Kojima, H. Tsutsui, et al.
Syndecan-4 Deficiency Limits Neointimal Formation After Vascular Injury by Regulating Vascular Smooth Muscle Cell Proliferation and Vascular Progenitor Cell Mobilization
Arterioscler Thromb Vasc Biol,
May 1, 2011;
31(5):
1066 - 1074.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Dangas, A. Caixeta, R. Mehran, H. Parise, A. J. Lansky, E. Cristea, B. R. Brodie, B. Witzenbichler, G. Guagliumi, J. Z. Peruga, et al.
Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction
Circulation,
April 26, 2011;
123(16):
1745 - 1756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Takeshita, K. Shishido, K. Sugitatsu, N. Okamura, S. Mizuno, K. Yaginuma, H. Suenaga, Y. Tanaka, J. Matsumi, S. Takahashi, et al.
In Vitro and Human Studies of a 4F Double-Coaxial Technique ("Mother-Child" Configuration) to Facilitate Stent Implantation in Resistant Coronary Vessels
Circ Cardiovasc Interv,
April 1, 2011;
4(2):
155 - 161.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. G. Aragam and D. L. Bhatt
Review: Antiplatelet Therapy in Acute Coronary Syndromes
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2011;
16(1):
24 - 42.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y. Onuma and P. W. Serruys
Bioresorbable Scaffold: The Advent of a New Era in Percutaneous Coronary and Peripheral Revascularization?
Circulation,
February 22, 2011;
123(7):
779 - 797.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Vink, M. T. Dirksen, M. J. Suttorp, J. G. P. Tijssen, J. van Etten, M. S. Patterson, T. Slagboom, F. Kiemeneij, and G. J. Laarman
5-Year Follow-Up After Primary Percutaneous Coronary Intervention With a Paclitaxel-Eluting Stent Versus a Bare-Metal Stent in Acute ST-Segment Elevation Myocardial Infarction: A Follow-Up Study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction With ST-Segment Elevation) Trial
J. Am. Coll. Cardiol. Intv.,
January 1, 2011;
4(1):
24 - 29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T.-H. Chen and R. Matyal
The Management of Antiplatelet Therapy in Patients With Coronary Stents Undergoing Noncardiac Surgery
Seminars in Cardiothoracic and Vascular Anesthesia,
December 1, 2010;
14(4):
256 - 273.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Caixeta, A. J. Lansky, P. W. Serruys, J. B. Hermiller, P. Ruygrok, Y. Onuma, P. Gordon, M. Yaqub, K. Miquel-Hebert, S. Veldhof, et al.
Clinical Follow-Up 3 Years After Everolimus- and Paclitaxel-Eluting Stents: A Pooled Analysis From the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials
J. Am. Coll. Cardiol. Intv.,
December 1, 2010;
3(12):
1220 - 1228.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Mauri, J. M. Massaro, S. Jiang, I. Meredith, W. Wijns, J. Fajadet, D. E. Kandzari, M. B. Leon, D. E. Cutlip, and K. P. Thompson
Long-Term Clinical Outcomes With Zotarolimus-Eluting Versus Bare-Metal Coronary Stents
J. Am. Coll. Cardiol. Intv.,
December 1, 2010;
3(12):
1240 - 1249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Niccoli, R. A. Montone, G. Ferrante, and F. Crea
The Evolving Role of Inflammatory Biomarkers in Risk Assessment After Stent Implantation
J. Am. Coll. Cardiol.,
November 23, 2010;
56(22):
1783 - 1793.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kanei, N. C. Nakra, Yili Huang, and J. T. Fox
Long-Term Outcome of Bifurcation Stenting With Drug-Eluting Stents
Angiology,
October 1, 2010;
61(7):
633 - 637.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. S. Brilakis, T. Y. Wang, S. V. Rao, S. Banerjee, S. Goldman, K. Shunk, B. Kar, D. R. Holmes Jr, D. Dai, C. T. Chin, et al.
Frequency and Predictors of Drug-Eluting Stent Use in Saphenous Vein Bypass Graft Percutaneous Coronary Interventions: A Report From the American College of Cardiology National Cardiovascular Data CathPCI Registry
J. Am. Coll. Cardiol. Intv.,
October 1, 2010;
3(10):
1068 - 1073.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Frelinger III, M. R. Barnard, M. L. Fox, and A. D. Michelson
The Platelet Activity After Clopidogrel Termination (PACT) Study
Circ Cardiovasc Interv,
October 1, 2010;
3(5):
442 - 449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Takano, M. Yamamoto, M. Mizuno, D. Murakami, T. Inami, N. Kimata, K. Murai, N. Kobayashi, K. Okamatsu, T. Ohba, et al.
Late Vascular Responses From 2 to 4 Years After Implantation of Sirolimus-Eluting Stents: Serial Observations by Intracoronary Optical Coherence Tomography
Circ Cardiovasc Interv,
October 1, 2010;
3(5):
476 - 483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Krone, S. V. Rao, D. Dai, H. V. Anderson, E. D. Peterson, M. A. Brown, R. G. Brindis, L. W. Klein, R. E. Shaw, W. S. Weintraub, et al.
Acceptance, Panic, and Partial Recovery: The Pattern of Usage of Drug-Eluting Stents After Introduction in the U.S. (A Report From the American College of Cardiology/National Cardiovascular Data Registry)
J. Am. Coll. Cardiol. Intv.,
September 1, 2010;
3(9):
902 - 910.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. F. Dineen, R. J. Curtin, and J. A. Harty
A review of the use of common antiplatelet agents in orthopaedic practice
J Bone Joint Surg Br,
September 1, 2010;
92-B(9):
1186 - 1191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Garg and P. W. Serruys
Coronary Stents: Current Status
J. Am. Coll. Cardiol.,
August 31, 2010;
56(10_Suppl_S):
S1 - S42.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Buch, B. D. Prendergast, and R. F. Storey
Antiplatelet therapy and vascular disease: an update
Therapeutic Advances in Cardiovascular Disease,
August 1, 2010;
4(4):
249 - 275.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. H. J. Pijls, W. F. Fearon, P. A. L. Tonino, U. Siebert, F. Ikeno, B. Bornschein, M. van't Veer, V. Klauss, G. Manoharan, T. Engstrom, et al.
Fractional Flow Reserve Versus Angiography for Guiding Percutaneous Coronary Intervention in Patients With Multivessel Coronary Artery Disease: 2-Year Follow-Up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) Study
J. Am. Coll. Cardiol.,
July 13, 2010;
56(3):
177 - 184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Smout and R. Naylor
Vascular surgery: operating on patients on clopidogrel or warfarin
Clin Risk,
July 1, 2010;
16(4):
135 - 140.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Gaglia Jr, R. Torguson, Z. Xue, M. A. Gonzalez, S. D. Collins, I. Ben-Dor, A. I. Syed, G. Maluenda, C. Delhaye, N. Hanna, et al.
Insurance Type Influences the Use of Drug-Eluting Stents
J. Am. Coll. Cardiol. Intv.,
July 1, 2010;
3(7):
773 - 779.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Krone
Selection of Patients for Drug-Eluting Stents Based on Insurance Coverage: Pay or Don't Play
J. Am. Coll. Cardiol. Intv.,
July 1, 2010;
3(7):
780 - 782.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. F. Zattera, A. M. Grande, R. Gaeta, M. Savasta, S. Lentini, and M. Vigano
Reconstruction of Anterior Descending Artery after Removal of Stents
Asian Cardiovasc Thorac Ann,
June 1, 2010;
18(3):
291 - 293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K. Natarajan, C. S. Ogilvy, L. N. Hopkins, A. H. Siddiqui, and E. I. Levy
Initial experience with an everolimus-eluting, second-generation drug-eluting stent for treatment of intracranial atherosclerosis.
JNIS,
June 1, 2010;
2(2):
104 - 109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. W. Lee, S. J. Kang, D. W. Park, S. H. Lee, Y. H. Kim, J. J. Kim, S. W. Park, G. S. Mintz, and S. J. Park
Intravascular Ultrasound Findings in Patients With Very Late Stent Thrombosis After Either Drug-Eluting or Bare-Metal Stent Implantation
J. Am. Coll. Cardiol.,
May 4, 2010;
55(18):
1936 - 1942.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Morrison
Stent Thrombosis: The Effect of Intention on Perception
J. Am. Coll. Cardiol.,
May 4, 2010;
55(18):
1943 - 1944.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Ducrocq, J. S. Wallace, G. Baron, P. Ravaud, M. J. Alberts, P. W. F. Wilson, E. M. Ohman, D. M. Brennan, R. B. D'Agostino, D. L. Bhatt, et al.
Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis
Eur. Heart J.,
May 2, 2010;
31(10):
1257 - 1265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Onuma, P. W. Serruys, N. Kukreja, S. Veldhof, J. Doostzadeh, S. Cao, G. W. Stone, and on behalf of the SPIRIT II and III Investigators
Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials
Eur. Heart J.,
May 1, 2010;
31(9):
1071 - 1078.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Cho, H. M. Yang, K. W. Park, W. Y. Chung, D. J. Choi, W. W. Seo, K. T. Jeong, S. C. Chae, M. Y. Lee, S. H. Hur, et al.
Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of ST-Segment Elevation Myocardial Infarction: With Analyses for Diabetic and Nondiabetic Subpopulation
J. Am. Coll. Cardiol. Intv.,
May 1, 2010;
3(5):
498 - 506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Garg and P. W Serruys
Drug-eluting stents: a reappraisal
Heart,
April 1, 2010;
96(7):
489 - 493.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. El-Menyar, H. Hussein, and J. Al Suwaidi
Coronary Stent Thrombosis in Patients With Chronic Renal Insufficiency
Angiology,
April 1, 2010;
61(3):
297 - 303.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Savonitto, M. D'Urbano, M. Caracciolo, F. Barlocco, G. Mariani, M. Nichelatti, S. Klugmann, and S. De Servi
Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel
Br. J. Anaesth.,
March 1, 2010;
104(3):
285 - 291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Nestor Kalinoski, R. S. Ramdath, K. M. Langenderfer, S. Sikanderkhel, S. DeRaedt, M. Welch, J. L. Park, T. Pringle, B. Joe, G. T. Cicila, et al.
Neointimal Hyperplasia and Vasoreactivity Are Controlled by Genetic Elements on Rat Chromosome 3
Hypertension,
February 1, 2010;
55(2):
555 - 561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Vasa-Nicotera and T. Gershlick
Chapter 29 Stent thrombosis
Oxford Textbook of Interventional Cardiology,
January 1, 2010;
1(1):
med-9780199569083-chapter - med-9780199569083-chapter.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. Shiroto, S. Yasuda, R. Tsuburaya, Y. Ito, J. Takahashi, K. Ito, H. Ishibashi-Ueda, and H. Shimokawa
Role of Rho-Kinase in the Pathogenesis of Coronary Hyperconstricting Responses Induced by Drug-Eluting Stents in Pigs In Vivo
J. Am. Coll. Cardiol.,
December 8, 2009;
54(24):
2321 - 2329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Kandzari, A. Farb, and A. B. Boam
Percutaneous Coronary Intervention in Perspective: Drug-Eluting Stents as a Model for Regulatory Review
Circ Cardiovasc Interv,
December 1, 2009;
2(6):
574 - 579.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Kandzari, D. J. Angiolillo, M. J. Price, and P. S. Teirstein
Identifying the "Optimal" Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Revascularization
J. Am. Coll. Cardiol. Intv.,
December 1, 2009;
2(12):
1279 - 1285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
American College of Cardiology Foundation, American Heart Association Task Force on Practice, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interve, Society for Vascular Medicine, Society for Vascular Surgery, L. A. Fleisher, et al.
2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery
J. Am. Coll. Cardiol.,
November 24, 2009;
54(22):
e13 - e118.
[Full Text]
[PDF]
|
|
|
|
|
|
|
2007 WRITING COMMITTEE MEMBERS, L. A. Fleisher, J. A. Beckman, K. A. Brown, H. Calkins, E. L. Chaikof, K. E. Fleischmann, W. K. Freeman, J. B. Froehlich, E. K. Kasper, et al.
2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Circulation,
November 24, 2009;
120(21):
e169 - e276.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Tebaldi, C. Arcozzi, G. Campo, G. Percoco, R. Ferrari, M. Valgimigli, and On behalf of the STRATEGY Investigators
The 5-Year Clinical Outcomes After a Randomized Comparison of Sirolimus-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction
J. Am. Coll. Cardiol.,
November 10, 2009;
54(20):
1900 - 1901.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Schulz, T. Schuster, J. Mehilli, R. A. Byrne, J. Ellert, S. Massberg, J. Goedel, O. Bruskina, K. Ulm, A. Schomig, et al.
Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period
Eur. Heart J.,
November 2, 2009;
30(22):
2714 - 2721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. RAYMOND and V. MENON
Dual antiplatelet therapy in coronary artery disease: A case-based approach
Cleveland Clinic Journal of Medicine,
November 1, 2009;
76(11):
663 - 670.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. R. Brodie, H. Wilson, T. Stuckey, M. Nussbaum, S. Laurent, B. Bradshaw, A. Humphrey, C. Metzger, J. Hermiller, F. Krainin, et al.
Outcomes With Drug-Eluting Versus Bare-Metal Stents in Saphenous Vein Graft Intervention: Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group
J. Am. Coll. Cardiol. Intv.,
November 1, 2009;
2(11):
1105 - 1112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Sera, M. Awata, M. Uematsu, J.-i. Kotani, S. Nanto, and S. Nagata
Optimal Stent-Sizing With Intravascular Ultrasound Contributes to Complete Neointimal Coverage After Sirolimus-Eluting Stent Implantation Assessed by Angioscopy
J. Am. Coll. Cardiol. Intv.,
October 1, 2009;
2(10):
989 - 994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-e. Obata, T. Nakamura, Y. Kitta, Y. Kodama, K. Sano, K.-I. Kawabata, Y. Saitoh, D. Fujioka, T. Kobayashi, T. Yano, et al.
Treatment of Acute Myocardial Infarction With Sirolimus-Eluting Stents Results in Chronic Endothelial Dysfunction in the Infarct-Related Coronary Artery
Circ Cardiovasc Interv,
October 1, 2009;
2(5):
384 - 391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K J Harjai, C Shenoy, P Orshaw, and J Boura
Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry
Heart,
October 1, 2009;
95(19):
1579 - 1586.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Menozzi, E. Solinas, P. Ortolani, A. Repetto, F. Saia, G. Piovaccari, A. Manari, E. Magagnini, L. Vignali, E. Bonizzoni, et al.
Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study
Eur. Heart J.,
September 1, 2009;
30(17):
2095 - 2101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Roe, A. Y. Chen, C. P. Cannon, S. Rao, J. Rumsfeld, D. J. Magid, R. Brindis, L. W. Klein, W. B. Gibler, E. M. Ohman, et al.
Temporal Changes in the Use of Drug-Eluting Stents for Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention From 2006 to 2008: Results From the Can Rapid risk stratification of Unstable angina patients Supress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) and Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (ACTION-GWTG) Registries
Circ Cardiovasc Qual Outcomes,
September 1, 2009;
2(5):
414 - 420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Tran, S. D. Barnett, S. L. Hunt, A. Chon, and N. Ad
The effect of previous coronary artery stenting on short- and intermediate-term outcome after surgical revascularization in patients with diabetes mellitus.
J. Thorac. Cardiovasc. Surg.,
August 1, 2009;
138(2):
316 - 323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. O. Lokhandwala, P. J.M. Best, J. H. Butterfield, K. A. Skelding, T. Scott, J. C. Blankenship, J. W. Buckley, and P. B. Berger
Frequency of Allergic or Hematologic Adverse Reactions to Ticlopidine Among Patients With Allergic or Hematologic Adverse Reactions to Clopidogrel
Circ Cardiovasc Interv,
August 1, 2009;
2(4):
348 - 351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Onuma, N. Kukreja, N. Piazza, J. Eindhoven, C. Girasis, L. Schenkeveld, R. van Domburg, P. W. Serruys, and Interventional Cardiologists of the Thoraxcenter (
The Everolimus-Eluting Stent in Real-World Patients: 6-Month Follow-Up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) Registry
J. Am. Coll. Cardiol.,
July 14, 2009;
54(3):
269 - 276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Holmes Jr, D. J. Kereiakes, N. S. Kleiman, D. J. Moliterno, G. Patti, and C. L. Grines
Combining Antiplatelet and Anticoagulant Therapies
J. Am. Coll. Cardiol.,
July 7, 2009;
54(2):
95 - 109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Chen, D. Hou, L. Pendyala, J. A. Goudevenos, and N. G. Kounis
Drug-Eluting Stent Thrombosis: The Kounis Hypersensitivity-Associated Acute Coronary Syndrome Revisited
J. Am. Coll. Cardiol. Intv.,
July 1, 2009;
2(7):
583 - 593.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Unverdorben, C. Vallbracht, B. Cremers, H. Heuer, C. Hengstenberg, C. Maikowski, G. S. Werner, D. Antoni, F. X. Kleber, W. Bocksch, et al.
Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis
Circulation,
June 16, 2009;
119(23):
2986 - 2994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Leon, D. J. Allocco, K. D. Dawkins, and D. S. Baim
Late Clinical Events After Drug-Eluting Stents: The Interplay Between Stent-Related and Natural History-Driven Events
J. Am. Coll. Cardiol. Intv.,
June 1, 2009;
2(6):
504 - 512.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-J. Park, Y.-H. Kim, D.-W. Park, S.-W. Lee, W.-J. Kim, J. Suh, S.-C. Yun, C. W. Lee, M.-K. Hong, J.-H. Lee, et al.
Impact of Intravascular Ultrasound Guidance on Long-Term Mortality in Stenting for Unprotected Left Main Coronary Artery Stenosis
Circ Cardiovasc Interv,
June 1, 2009;
2(3):
167 - 177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C.Y. To, G. Armstrong, I. Zeng, and M. W.I. Webster
Noncardiac Surgery and Bleeding After Percutaneous Coronary Intervention
Circ Cardiovasc Interv,
June 1, 2009;
2(3):
213 - 221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Prasad and D. R Holmes
Update on dual antiplatelet therapy for percutaneous coronary intervention
Heart,
June 1, 2009;
95(11):
861 - 865.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Rzucidlo
Signaling Pathways Regulating Vascular Smooth Muscle Cell Differentiation
Vascular,
June 1, 2009;
17(suppl_1):
S15 - S20.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. T. Ko, M. Chiu, H. Guo, P. C. Austin, R. Goeree, E. Cohen, M. Labinaz, and J. V. Tu
Safety and Effectiveness of Drug-Eluting and Bare-Metal Stents for Patients With Off- and On-Label Indications
J. Am. Coll. Cardiol.,
May 12, 2009;
53(19):
1773 - 1782.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Douglas, J. M. Brennan, K. J. Anstrom, A. Sedrakyan, E. L. Eisenstein, G. Haque, D. Dai, D. F. Kong, B. Hammill, L. Curtis, et al.
Clinical Effectiveness of Coronary Stents in Elderly Persons: Results From 262,700 Medicare Patients in the American College of Cardiology-National Cardiovascular Data Registry
J. Am. Coll. Cardiol.,
May 5, 2009;
53(18):
1629 - 1641.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Nesbitt
Perioperative bleeding: an anaesthetic perspective
Clin Risk,
May 1, 2009;
15(3):
96 - 100.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Cleanthis and M. Flather
The dangers of stopping clopidogrel perioperatively: a cardiologist's perspective
Clin Risk,
May 1, 2009;
15(3):
106 - 108.
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Liu, H. Doi, A. Maehara, G. S. Mintz, J. de Ribamar Costa Jr, K. Sano, G. Weisz, G. D. Dangas, A. J. Lansky, E. M. Kreps, et al.
A Volumetric Intravascular Ultrasound Comparison of Early Drug-Eluting Stent Thrombosis Versus Restenosis
J. Am. Coll. Cardiol. Intv.,
May 1, 2009;
2(5):
428 - 434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Moore, P. Barlis, J. Spiro, G. Ghimire, M. Roughton, C. Di Mario, W. Wallis, C. Ilsley, A. Mitchell, M. Mason, et al.
A Randomized Optical Coherence Tomography Study of Coronary Stent Strut Coverage and Luminal Protrusion With Rapamycin-Eluting Stents
J. Am. Coll. Cardiol. Intv.,
May 1, 2009;
2(5):
437 - 444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Awata, S. Nanto, M. Uematsu, T. Morozumi, T. Watanabe, T. Onishi, O. Iida, F. Sera, H. Minamiguchi, J.-i. Kotani, et al.
Heterogeneous Arterial Healing in Patients Following Paclitaxel-Eluting Stent Implantation: Comparison With Sirolimus-Eluting Stents
J. Am. Coll. Cardiol. Intv.,
May 1, 2009;
2(5):
453 - 458.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Otake, J. Shite, J. Ako, T. Shinke, Y. Tanino, D. Ogasawara, T. Sawada, N. Miyoshi, H. Kato, B.-K. Koo, et al.
Local Determinants of Thrombus Formation Following Sirolimus-Eluting Stent Implantation Assessed by Optical Coherence Tomography
J. Am. Coll. Cardiol. Intv.,
May 1, 2009;
2(5):
459 - 466.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Weisz, M. B. Leon, D. R. Holmes Jr, D. J. Kereiakes, J. J. Popma, P. S. Teirstein, S. A. Cohen, H. Wang, D. E. Cutlip, and J. W. Moses
Five-Year Follow-Up After Sirolimus-Eluting Stent Implantation: Results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial
J. Am. Coll. Cardiol.,
April 28, 2009;
53(17):
1488 - 1497.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. van Werkum, A. A. Heestermans, A. C. Zomer, J. C. Kelder, M.-J. Suttorp, B. J. Rensing, J. J. Koolen, B.R. G. Brueren, J.-H. E. Dambrink, R. W. Hautvast, et al.
Predictors of Coronary Stent Thrombosis: The Dutch Stent Thrombosis Registry
J. Am. Coll. Cardiol.,
April 21, 2009;
53(16):
1399 - 1409.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Li, Z. Zheng, B. Xu, S. Zhang, W. Li, R. Gao, and S. Hu
Comparison of Drug-Eluting Stents and Coronary Artery Bypass Surgery for the Treatment of Multivessel Coronary Disease: Three-Year Follow-Up Results From a Single Institution
Circulation,
April 21, 2009;
119(15):
2040 - 2050.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chua and A. Ignaszewski
Clopidogrel in acute coronary syndromes
BMJ,
April 14, 2009;
338(apr14_1):
b1180 - b1180.
[Full Text]
|
|
|
|
|
|
|
J. M. Ruiz-Nodar, F. Marin, J. Sanchez-Paya, J. A. Hurtado, J. Valencia-Martin, S. Manzano-Fernandez, V. Roldan, V. Perez-Andreu, F. Sogorb, M. Valdes, et al.
Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation
Eur. Heart J.,
April 2, 2009;
30(8):
932 - 939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Han, Q. Jing, B. Xu, L. Yang, H. Liu, X. Shang, T. Jiang, Z. Li, H. Zhang, H. Li, et al.
Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in "Real-World" Practice: 18-Month Clinical and 9-Month Angiographic Outcomes
J. Am. Coll. Cardiol. Intv.,
April 1, 2009;
2(4):
303 - 309.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
